A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 4, 2014

Primary Completion Date

September 13, 2016

Study Completion Date

September 13, 2016

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Placebo

Placebo

BIOLOGICAL

PF-06342674 Dose A

Multiple SC Doses

BIOLOGICAL

PF-06342674 Dose B

Multiple SC Doses

BIOLOGICAL

PF-06342674 Dose C

Multiple SC Doses

BIOLOGICAL

PF-06342674 Dose D

Multiple SC Doses

Trial Locations (21)

27710

Duke Clinical Research Unit, Durham

Duke University Health Systems (DUHS) Investigational Drug Services, Durham

30318

Atlanta Diabetes Associates, Atlanta

55454

University Of Minnesota Fairview Pharmacy Services, Minneapolis

55455

University Of Minnesota Medical School, Minneapolis

60637

Duchossois Center for Advanced Medicine, Chicago

The University of Chicago Medical Center, Chicago

University of Chicago Clinical Resource Center, Chicago

University of Chicago Medical Center, Chicago

63110

Barnes- Jewish HOSP Att: Kathryn Vehe, St Louis

Washington University - Center for Advanced Medicine, St Louis

Washington University, St Louis

80045

Barbara Davis Center, Aurora

92161

VA San Diego Healthcare System (Drug Shipment), San Diego

Veterans Administration San Diego Healthcare System, San Diego

94143

University of California, San Francisco, San Francisco

06510

Yale School of Medicine, New Haven

06511

Yale New Haven Hospital - Investigational Drug Services, New Haven

06519

Yale University School of Medicine, New Haven

01655

Umass Memorial Medical Center, Worcester

University of Massachusetts Medical School, Worcester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY